News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
489,349 Results
Type
Article (8158)
Company Profile (143)
Press Release (481048)
Multimedia
Podcasts (4)
Webinars (7)
Section
Business (166909)
Career Advice (307)
Deals (25771)
Drug Delivery (7)
Drug Development (53003)
Employer Resources (14)
FDA (9797)
Job Trends (8601)
News (238517)
Policy (17929)
Tag
2025 Best Places to Work (1)
2026 Best Places to Work (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (8)
2027 Biotech Beach Elite (1)
2027 Biotech Beach Standard (3)
2027 Genetown Elite (2)
2027 Genetown Premier (1)
2027 Genetown Standard (2)
2027 Pharm Country Digital (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (504)
Accelerated approval (33)
ADA (18)
Adcomms (1)
Allergies (103)
Alliances (33188)
ALS (123)
Alzheimer's disease (1006)
Antibody-drug conjugate (ADC) (332)
Approvals (10521)
Artificial intelligence (378)
ASCO (161)
Autoimmune disease (243)
Automation (34)
Bankruptcy (264)
Belgium (4)
Best Places to Work (6978)
BIO (36)
Biologics (49)
BIOSECURE Act (1)
Biosimilars (126)
BioSpace Insights (17)
Biotechnology (89)
Bispecific (24)
Bladder cancer (145)
Brain cancer (36)
Breast cancer (549)
Cancer (4067)
Cardiovascular disease (243)
Career advice (248)
Career pathing (1)
CAR-T (187)
CDC (2)
CDMO (31)
Celiac Disease (3)
Cell therapy (516)
Cervical cancer (36)
Clinical research (48615)
Collaboration (1375)
Commercialization (29)
Compensation (1630)
Complete response letters (36)
COVID-19 (780)
CRISPR (69)
C-suite (867)
Cystic fibrosis (89)
Data (6456)
Denatured (4)
Depression (108)
Dermatology (100)
Diabetes (385)
Diagnostics (4283)
Digital health (42)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (175)
Drug pricing (7)
Drug shortages (3)
Duchenne muscular dystrophy (206)
Earnings (74149)
Editorial (1)
Employer branding (2)
Employer resources (14)
ESMO (237)
Events (89031)
Executive appointments (742)
Eye disease (5)
FDA (12747)
Fibrodysplasia Ossificans Progressiva (12)
Fragile X (1)
Friedreich's ataxia (20)
Frontotemporal dementia (25)
Funding (1013)
Gene editing (133)
Generative AI (14)
Gene therapy (358)
GLP-1 (317)
Government (963)
Grass and pollen (2)
Guidances (284)
Healthcare (9425)
Hematology (96)
HIV (58)
Huntington's disease (29)
Idiopathic pulmonary fibrosis (5)
IgA nephropathy (82)
Immunology and inflammation (117)
Immuno-oncology (72)
Indications (186)
Infectious disease (988)
Inflammatory bowel disease (142)
Inflation Reduction Act (4)
Influenza (89)
Intellectual property (272)
Interviews (41)
IPO (12414)
IRA (2)
Job creations (1975)
Job search strategy (238)
JPM (1)
Kidney cancer (19)
Kidney disease (89)
Labor market (2)
Layoffs (60)
Legal (5202)
Licensing (53)
Liver cancer (47)
Longevity (27)
Lung cancer (585)
Lung diease (9)
Lymphoma (277)
Machine learning (30)
Management (3)
Manufacturing (625)
Marketing (22)
MASH (123)
Medical affairs (2)
Medical device (8739)
Medtech (8932)
Mergers & acquisitions (14498)
Metabolic disorders (778)
mRNA (74)
Multiple sclerosis (119)
Multispecific (3)
NASH (4)
Netherlands (3)
Neurodegenerative disease (245)
Neuropsychiatric disorders (41)
Neuroscience (1965)
Neurotech (2)
NextGen: Class of 2026 (3161)
Non-profit (849)
Obesity (244)
Opinion (15)
Ovarian cancer (182)
Pain (194)
Pancreatic cancer (233)
Parkinson's disease (218)
Partnered (12)
Patents (527)
Patient advocacy (3)
Patient recruitment (551)
Patient selection (47)
Peanut (33)
People (41588)
Peptides (18)
Pharmaceutical (30)
Pharmacy benefit managers (11)
Phase 1 (15672)
Phase 2 (21709)
Phase 3 (14703)
Pipeline (8598)
Policy (20)
Postmarket research (1576)
Preclinical (6608)
Press Release (34)
Prostate cancer (210)
Psychedelics (10)
Radiopharmaceuticals (203)
Rare diseases (642)
Real estate (3035)
Recruiting (6)
Regenerative medicine (13)
Regulatory (15259)
Reports (23)
Research institute (596)
Resumes & cover letters (45)
Rett syndrome (47)
RNA editing (9)
RSV (51)
Schizophrenia (111)
Series A (179)
Series B (127)
Service/supplier (5)
Sickle cell disease (67)
Spinal muscular atrophy (93)
Sponsored (6)
Startups (2032)
Stem cells (2)
Stomach cancer (3)
Substance use disorders (17)
Supply chain (57)
Switzerland (1)
Tariffs (3)
Vaccines (354)
Venture capital (21)
Weight loss (78)
Wet AMD (3)
Women's health (101)
Date
Today (140)
Last 7 days (536)
Last 30 days (1884)
Last 365 days (19350)
2026 (16269)
2025 (19307)
2024 (23036)
2023 (26577)
2022 (34647)
2021 (37222)
2020 (33513)
2019 (23311)
2018 (17506)
2017 (18793)
2016 (17956)
2015 (24323)
2014 (21709)
2013 (18163)
2012 (20252)
2011 (20471)
2010 (20347)
Location
Africa (235)
Alabama (80)
Alaska (2)
Arizona (325)
Arkansas (12)
Asia (18141)
Australia (2138)
California (13075)
Canada (3402)
China (590)
Colorado (534)
Connecticut (457)
Delaware (232)
Europe (25049)
Florida (1958)
Georgia (412)
Hawaii (3)
Idaho (46)
Illinois (789)
India (65)
Indiana (337)
Iowa (19)
Japan (463)
Kansas (104)
Kentucky (33)
Louisiana (28)
Maine (27)
Maryland (1291)
Massachusetts (8549)
Michigan (323)
Minnesota (609)
Mississippi (5)
Missouri (84)
Montana (20)
Nebraska (11)
Nevada (135)
New Hampshire (61)
New Jersey (2872)
New Mexico (12)
New York (3064)
North Carolina (1393)
North Dakota (4)
Northern California (6625)
Ohio (308)
Oklahoma (15)
Oregon (17)
Pennsylvania (2431)
Puerto Rico (24)
Rhode Island (32)
South America (409)
South Carolina (81)
South Dakota (1)
Southern California (5461)
Tennessee (128)
Texas (2150)
United States (42342)
Utah (399)
Vermont (1)
Virginia (168)
Washington D.C. (40)
Washington State (1001)
West Virginia (1)
Wisconsin (82)
Wyoming (1)
489,349 Results for "velos inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
LEX Diagnostics Receives FDA 510(k) Clearance and CLIA Waiver for LEX VELO System
February 16, 2026
·
2 min read
Press Releases
FDA Approves Genentech’s Lunsumio VELO™ for Subcutaneous Use in Relapsed or Refractory Follicular Lymphoma
December 22, 2025
·
16 min read
Press Releases
FDA approves Roche’s Lunsumio VELO™ for subcutaneous use in relapsed or refractory follicular lymphoma
December 22, 2025
·
8 min read
Press Releases
LEX Diagnostics Submits Dual Applications for FDA 510(k) Clearance and CLIA Waiver for Groundbreaking LEX VELO System
June 9, 2025
·
3 min read
Drug Development
HanAll Biopharma Announces Initiation of Phase III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for Treatment of Dry Eye Disease
HanAll Biopharma Co., Ltd. (KRX: 009420. KS) announced the initiation of a Phase III VELOS-4 trial evaluating the efficacy and safety of tanfanercept, a novel, topical anti-inflammatory treatment in participants with moderate to severe dry eye disease (DED).
May 3, 2024
·
7 min read
Press Releases
Velo3D Announces the Commencement of OTCQX Trading
September 11, 2024
·
3 min read
Press Releases
Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) FY26
October 1, 2026
·
2 min read
Press Releases
Genentech’s Lunsumio-Based Regimen Significantly Improves Progression-Free Survival in Follicular Lymphoma in Phase III CELESTIMO Study
September 17, 2026
·
15 min read
Drug Development
HanAll Biopharma Announces Results from Phase III randomized, double-masked active treatment-controlled VELOS-3 Trial Evaluating Tanfanercept 0.25% for Treatment of Dry Eye Disease
HanAll Biopharma Co., Ltd. announced results from the Phase III VELOS-3 trial evaluating the safety and efficacy of tanfanercept, a novel, topical anti-inflammatory treatment being studied for the treatment of dry eye disease (DED) in subjects diagnosed with moderate to severe DED.
May 19, 2023
·
7 min read
Press Releases
Mint Pharmaceuticals Inc. and Bayer Inc. Expand Distribution Partnership in Canada
October 6, 2026
·
3 min read
1 of 48,935
Next